Clinical trials for stomach and esophageal cancer

69 currently recruiting clinical trials

Early Access Stomach and esophageal cancer
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
MSD
Merck Sharp & Dohme LLC
Early Access Stomach and esophageal cancer
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 PDL1 Negative (< 1%) None Systemic Treatment-Naive
HER2
Astellas
Astellas Pharma Développement mondial, Inc.
Phase 3 Stomach and esophageal cancer #NCT06356311
Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre François Baclesse (Caen ), Centre Hospitalier Universitaire de Toulouse (Toulouse), Institut Bergonié (Bordeaux) (and 3 more...)
Merck Sharp & Dohme LLC
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer #NCT07087054 #2024-519875-24-00
Neuroendocrine tumor None
Hôpital de la Timone AP-HM (Marseille), Hôpital Trousseau - CHRU Hôpitaux de Tours (Chambray-lès-Tours), Centre Antoine Lacassagne (Nice), Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital Beaujon (Clichy) (and 1 more...)
Crinetics Pharmaceuticals Inc.
Phase 3 Stomach and esophageal cancer #NCT03042169
Stomach Adenocarcinoma Metastatic None Systemic Treatment-Naive
Surgery Radiotherapy
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Hôpital universitaire de Lille
Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
HER2 Immunotherapy Chemotherapy
Centre Hospitalier Universitaire de Lille (Lille), Hôpital Saint Louis AP-HP (Paris), Hôpital Saint Antoine AP-HP (Paris), Centre Henri Becquerel (Rouen ), CHU Caen Normandie (Caen) (and 12 more...)
Astellas Pharma Développement mondial, Inc.
Phase 3 Stomach and esophageal cancer #NCT06764875 #2024-512583-57-00
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
Gustave Roussy (Villejuif), Centre François Baclesse (Caen ), Centre Léon Bérard (Lyon), Centre Eugene Marquis (Rennes)
AstraZeneca
Phase 3 Stomach and esophageal cancer #NCT06644781 #2023-509630-19-00
Esophagus Squamous cell carcinoma Locally Advanced Metastatic 1 Immunotherapy Chemotherapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Lille (Lille), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Hôpital Saint Antoine AP-HP (Paris)
Daiichi Sankyo
Phase 3 Stomach and esophageal cancer #NCT04460352 #2022-500966-82-00
Esophagus Squamous cell carcinoma Locally Advanced None Systemic Treatment-Naive
Chemotherapy Radiotherapy
Hôpital Alexandra Lepève - Centre Hospitalier de Dunkerque (Dunkerque), Centre Hospitalier Universitaire de Lille (Lille)
Karolinska University Hospital
Phase 3 Stomach and esophageal cancer #NCT05152147 #2023-510319-20-00
Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic HER2 None Systemic Treatment-Naive
Immunotherapy Chemotherapy
Hôpital Saint Antoine AP-HP (Paris)
Jazz Pharmaceuticals